Theranovir Named Finalist at the Trophées PME RMC BFM - Celebrating Innovation and Creativity

We are proud to announce that Theranovir was selected as a finalist for the Trophées PME RMC BFM – 1er Concours des PME de France, under the “Innovative and Creative” category. Being recognised among some of France’s most forward-thinking small and medium enterprises is a tremendous honour and a testament to our team’s commitment to pushing the boundaries of science and innovation.

About the Competition

The Trophées PME RMC BFM are organised by RMC and BFM, two of France's leading media outlets, in partnership with regional and national business networks including Chambres de Commerce et d'Industrie (CCI). Now in its 16e edition, the competition aims to highlight and reward the innovation, resilience and impact of French PMEs across six categories; Innovative and Creative, Durable, Solidaire et Éco-responsable, Export, Jeune Pousse, Transformation, Fabriqué en France and Artisanale.

Thousands of companies from across France participate each year, making this a highly competitive event. Regional juries select finalists who then compete at the national level, giving participants not only recognition but also incredible media exposure, networking opportunities and credibility in the entrepreneurial ecosystem. Winners receive advertising packages on RMC and BFM, media coverage and a video profiling their company, a significant boost for visibility and reputation.

A Celebration of Innovation

The Trophées PME RMC BFM highlights companies that embody the entrepreneurial spirit driving France’s economic growth, those that innovate, adapt, and contribute to shaping the industries of tomorrow. At Theranovir, our mission has always been to revolutionise healthcare through cutting-edge immunotherapy, developing NOV2-based antibody solutions targeting cancer, obesity, and infectious diseases.

Being selected as a finalist in such a competitive and prestigious event reinforces our belief in the impact and potential of our scientific approach.

Our Presence at the Event

For the occasion, our team prepared an engaging stand to showcase our mission, research, and innovative pipeline, highlighting the scientific foundation behind our NOV2 antibody platform and its potential applications. Visitors were drawn to our visuals and discussions about how Theranovir bridges cutting-edge research with real-world therapeutic impact.

We had the pleasure of meeting and speaking with entrepreneurs, investors, healthcare professionals, students, and curious minds who stopped by to learn more about what drives our work. Many shared their own perspectives on innovation and the future of biotechnology, sparking meaningful conversations and potential collaborations.

The enthusiasm and insightful exchanges throughout the day were a powerful reminder of the growing momentum around French biotech innovation, and how companies like Theranovir are contributing to a future where science, creativity, and compassion come together to transform healthcare.

A Moment of Pride

Although we did not take home the final prize, being recognised as a finalist was an incredible milestone for our young and ambitious company. It reflects not only the creativity and scientific dedication of our team but also the trust and support of everyone who believes in our vision.

We extend our heartfelt thanks to RMC, BFM, and the Trophées PME jury for this opportunity, and to everyone who visited our stand and showed interest in our work.

At Theranovir, this recognition motivates us to continue innovating, collaborating, and pushing forward, one step closer to delivering breakthrough therapies that can make a lasting impact on patients’ lives.